Skip to main content

Table 2 Adverse events of any cause and any grade occurring in ≥10% of patients in either treatment group in the updated analysis of the CASPIAN trial (safety population) [12]

From: Durvalumab: A Review in Extensive-Stage SCLC

Adverse event DUR + EP (n = 265)
[% of pts] 		EP (n = 266)
[% of pts]
Neutropenia 42 47
Anaemia 38 47
Nausea 34 33
Alopecia 32 34
↓ appetite 18 17
Fatigue 18 17
Constipation 17 19
Asthenia 16 15
Thrombocytopenia 15 20
Vomiting 15 17
Cough 13 7
Dyspnoea 12 11
Leukopenia 11 12
Diarrhoea 11 11
↓ neutrophil count 10 12
Hyponatraemia 10 5
Hyperthyroidism 10 < 1
  1. DUR durvalumab, EP platinum (investigator’s choice of either carboplatin or cisplatin) plus etoposide, pts patients, ↓ decreased
Back to article page